ADPKD Guide Evidence-first

ADPKD treatment, research, diet, trials, and symptoms in one readable place

A mobile-first, evidence-first guide for people who want clear ADPKD guidance grounded in actual evidence.

Last reviewed: July 23, 2026

How to use this site

Who it is for: patients, families, and clinicians who want evidence-weighted ADPKD guidance without miracle-claim noise.
What it uses: trial data, guidelines, and tracked research updates ranked by evidence strength.
What it is not: personal medical advice or a cure-claims funnel dressed up as education.
How fresh it is: each page shows the latest review date pulled from the research pipeline.

Questions answered from peer-reviewed journals and approved drug data only. No marketing, no miracle claims. Works in any language.

Best first stop for patients and families.

What helps now — tolvaptan, BP control, and the evidence ladder.

Every approach ranked by evidence strength — from Tier 1 to failed.

Trials, cure research, and what changed recently.

Key new evidence this run , GLPG2737 / CFTR inhibition failed in the phase 2a MANGROVE study: it did not reduce htTKV growth or slow eGFR decline versus placebo in rapidly progressive ADPKD (PMID42201338).
Four-track review outcome
What strengthened , The negative CFTR result cleaned up a weak hypothesis.